参考文献/References:
[1]Ampie L, Choy W, LamanoJb, et al. Safety and outcomes of preoperative embolization of intracranial hemangioblastomas: a systematic review [J]. Clin Neurol Neurosur, 2016, 150: 143-151.
[2]Shmueli MD, Levy-Kanfo L, Haj E, et al. Arginine refolds, stabilizes, and restores function of mutant pVHL proteins in animal model of the VHL cancer syndrome [J]. Oncogene, 2019, 38(7): 1038-1049.
[3]Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene [J]. Nat Rev Cancer, 2015, 15(1): 55-64.
[4]Kim BY, Jonasch E, Mccutcheon IE. Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case report [J]. Target Oncol, 2012, 7(2): 145-149.
[5]Hwang SH, Bang S, Kim W, et al. Von Hippel-Lindau tumor suppressor (VHL) stimulates TOR signaling by interacting with phosphoinositide 3-kinase (PI3K) [J]. J Biol Chem, 2020, 295(8): 2336-2347.
[6]Roof AK, Gutierrez-Hartmann A. Consider the context: Ras/ERK and PI3K/AKT/mTOR signaling outcomes are pituitary cell type-specific [J]. Mol Cell Endocrinol, 2018, 463: 87-96.
[7]Sevilla-Montero J, Bienes-Martínez R, Labrousse-Arias D, et al. pVHL-mediated regulation of the anti-angiogenic protein thrombospondin-1 decreases migration of clear cell renal carcinoma cell lines [J]. Sci Rep, 2020, 10(1): 1175-1180.
[8]Vikkath N, Ariyannur P, Menon Kn, et al. Exploring the role of defective fibronectin matrix assembly in the VHL-asso-ciated CNS hemangioblastoma [J]. Drug Metab Pers Ther, 2018, 33(3): 127-134.
[9]Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis [J]. Nature, 2005, 436(7051): 725-730.
[10]Young AP, Schlisio S, MinamishimaYA, et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400 [J]. Nat Cell Biol, 2008, 10(3): 361-369.
[11]Guo Y, Schoell MC, Freeman RS. The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIM (EL) [J]. Oncogene, 2009, 28(16): 1864-1874.
[12]Li S, Rodriguez J, Li W, et al. EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance [J]. Proc Natl Acad Sci USA, 2019, 116(34): 16997-17006.
[13]Kang HM, Noh KH, Chang TK, et al. Ubiquitination of MAP1LC3B by pVHL is associated with autophagy and cell death in renal cell carcinoma [J]. Cell Death Dis, 2019, 10(4): 279-287.
[14]Datta K, Mondal S, Sinha S, et al. Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma [J]. Oncogene, 2005, 24(53): 7850-7858.
[15]Xin H, Brown JA, Gong C, et al. Association of the von Hippel-Lindau protein with AUF1 and posttranscriptional regulation of VEGFA mRNA [J]. Mol Cancer Res, 2012, 10(1): 108-120.